Oramed Pharmaceuticals (ORMP)

P/S ratio as of March 2026 (TTM): 65.7

According to Oramed Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.6499. At the end of 2025 the company had a P/S ratio of 49.4.

P/S ratio history for Oramed Pharmaceuticals from 2009 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	49.4
2024	N/A	-100%
2023	69.5	-60.05%
2022	174	-35.72%
2021	271	623.54%
2020	37.4	31.86%
2019	28.4	0.56%
2018	28.2	-46.97%
2017	53.2	-18.27%
2016	65.1
2015	N/A
2014	N/A
2013	N/A
2012	N/A
2011	N/A
2010	N/A
2009	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Novo Nordisk NVO	3.39	-94.85%	🇩🇰 Denmark
Sanofi SNY	2.13	-96.76%	🇫🇷 France
Ultragenyx Pharmaceutical RARE	2.76	-95.81%	🇺🇸 USA
Lexicon Pharmaceuticals LXRX	9.63	-85.36%	🇺🇸 USA
Compugen CGEN	28.1	-57.21%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Oramed Pharmaceuticals (ORMP)

P/S ratio as of March 2026 (TTM): 65.7